NCT01166477

Clinical Trial, Open-label, Randomised, in Order to Compare the Quality of Life for Those VIH+ Patients That Start With Monotherapy on LPV/r Tablets Vs. Triple Therapy With a Boosted Protease Inhibitor

Ensayo clínico, Abierto, Aleatorizado Para Comparar la Calidad de Vida de Los Pacientes VIH+ Que Inician Monoterapia Con Comprimidos de LPV/r vs Triple Terapia Que Contenga un IP Potenciado

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 228 (actual)
• Sponsor: Sociedad Andaluza de Enfermedades Infecciosas · Network
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The Study will help to compare the Quality of Life for those HIV patients that are on monotherapy with LPV/r Vs. triple therapy with a boosted protease inhibitor

Detailed description

The Study will help to compare the Quality of Life for those HIV patients that are on monotherapy with LPV/r Vs. triple therapy with a boosted protease inhibitor.

Conditions

• HIV Infection

Interventions

Type	Name	Description
DRUG	Lopinavir and ritonavir	The patients will take Kaletra (lopinavir200mg/ritonavir50mg)two tablets bid
DRUG	Triple therapy with ritonavir	The patients will continue to take their usual triple therapy, as established in the summary of product characteristics

Timeline

• Start date: 2010-01-01
• Primary completion: 2011-12-01
• Completion: 2011-12-01
• First posted: 2010-07-21
• Last updated: 2013-03-20

Locations

31 sites across 1 country: Spain